Uterine Cervical Neoplasms Clinical Trial
— SUCCEEDEROfficial title:
Sexual Function, Coping and Dyadic Coping in Cervical Cancer Patients: a Comparison Between Surgery and Radiotherapy Plus Chemotherapy
NCT number | NCT06124040 |
Other study ID # | 6044 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 23, 2023 |
Est. completion date | October 31, 2024 |
Verified date | October 2023 |
Source | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The studies currently available in the literature about sexual function and coping in cervical cancer are poor and heterogeneous, and their results are often conflicting; therefore, no definitive recommendations can be formulated. Furthermore, it is unclear whether the dysfunction is attributable to surgical sequelae, radiotherapy, chemotherapy, or psychological aspects related to cancer. Moreover, a baseline evaluation about sexual function and coping if often lacking. Aim of this protocol is to perform a prospective longitudinal study to compare surgical vs. radio-chemotherapy cervical cancer patients, with the following objectives: - To assess sexual function, coping, emotional distress, and quality of life of patients with cervical cancer undergoing surgery vs radiotherapy plus chemotherapy. - To evaluate changes on the previous variables over 6 months. The results obtained will be utilized for: - planning precocious psycho-educational interventions aimed at promoting psychological and couple well-being in cervical cancer patients since diagnosis - develop tools and educational programs for more appropriate communication about intimacy between healthcare professionals and patients.
Status | Recruiting |
Enrollment | 154 |
Est. completion date | October 31, 2024 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Patients' age = 18 years - Patients undergoing non-conservative surgery or radiotherapy plus chemotherapy - Patients able to understand and sign informed consent Exclusion Criteria: - Patients' age > 65 years - Patients with inability to express informed consent - Patients denying informed consent - Patients with psychopathological disturbances preexisting to the cancer diagnosis - Patients affected by severe language deficits |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Policlinico Agostino Gemelli IRCCS | Roma | RM |
Lead Sponsor | Collaborator |
---|---|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess sexual function in cervical cancer patients | Primary outcome is to assess sexual function of cervical cancer patients undergoing surgery vs patients undergoing radiotherapy plus chemotherapy.
This dimension will be assessed by "Female Sexual Function Index" (FSFI), a survey measuring the sexual functioning of women in six different domains: desire, arousal, lubrication, orgasm, satisfaction and pain. The index only measures sexual function in these domains over the previous 30 days. The FSFI can be used as a screening tool and as a potential diagnostic aid. A total cut-off score = 26.55 has been proposed for the diagnosis of female sexual dysfunction, so any woman scoring below 26.55 should be considered at risk for sexual dysfunction. |
6 months. Time 0: the day of the beginning of the treatment (surgery or radio-chemotherapy), and Time 1: 6 months from the first assessment. | |
Primary | Assess individual coping strategies in cervical cancer patients | Assessment of individual coping strategies will be done in both groups by The Mini-Mental Adjustment to Cancer (Mini-MAC), a 29-item instrument that evaluates cognitive and behavioral responses to cancer. The factors of the Mini-MAC are: Fighting Spirit, Hopelessness, Anxious Preoccupation, Fatalism, and Cognitive Avoidance. Each item is rated on a 4-point scale that ranges from "definitely does not apply to me" to "definitely applies to me".
Each statement is rated on a scale from 1 (definitely not) to 4 (definitely yes), and the available scores for each of the four coping strategies range from 7 to 28 points. The higher the score, the greater the coping/behavior style in the patient's fight against cancer. |
6 months. Time 0: the day of the beginning of the treatment (surgery or radio-chemotherapy), and Time 1: 6 months from the first assessment. | |
Secondary | Evaluate dyadic coping in cervical cancer patients | Dyadic Adjustment Scale (DAS) will be adopted to assess the quality of romantic relationships in both patient and her partner, if any.
This tool evaluates the adaptability, quality, and representation that each partner has with regard to an intimate relationship. It is a self-reporting questionnaire consisting of 32 items, divided into four subscales: dyadic satisfaction, dyadic cohesive, dyadic and affective consent. For this test there is not a real clinical cut-off, the higher the score the greater the cohesion within the couple. Minimum and maximum scores depend on the subscales: Suscale CONSENT ON IMPORTANT ISSUES: minimum score 0, maximum 4 Subscale SATISFACTION WITH THE STATUS OF THE RELATIONSHIP: minimum score 0, maximum 5 Subscale DOING TOGETHER: minimum score 0, maximum 4 Subscale SATISFACTION FOR AFFECTIVE AND SEXUAL LIFE: minimum score 0, maximum 5 |
6 months. Time 0: the day of the beginning of the treatment (surgery or radio-chemotherapy), and Time 1: 6 months from the first assessment. | |
Secondary | Evaluate emotional Distress in cervical cancer patients | Both groups will be administred by Distress Thermometer (DT), to evaluate emotional distress.
Clinical cut-off are considered as follow: DT: > or = 4 (scoring equal or higher than 4 means high emotional distress). |
6 months. Time 0: the day of the beginning of the treatment (surgery or radio-chemotherapy), and Time 1: 6 months from the first assessment. | |
Secondary | Evaluate Anxiety and Depression in cervical cancer patients | Both groups will be administred by Hospital Anxiety and Depression Scale (HADS), to evaluate anxiety and depression.
Clinical cut-off are considered as follow: HADS: 8-10 (a score lower than 8 means physiological levels of anxiety and depression; scores between 8 and 10 means the presence of anxiety and depression; scoring higher than 10 means high levels of anxiety and depression). |
6 months. Time 0: the day of the beginning of the treatment (surgery or radio-chemotherapy), and Time 1: 6 months from the first assessment. | |
Secondary | Evaluate the presence of any dissociative symtoms in cervical cancer patients | The Dissociative Experience Scale (DES-II) measures a wide variety of dissociation types, including both problematic experiences and normal experiences (e.g., daydreaming). It is a screening tool for dissociative disorders, especially dissociative identity disorder and dissociative disorder not otherwise specified.
It is a 28-item questionnaire answered on a percentage scale ranging from 0% to 100%. The total score can be between 0 and 100, and is obtained by dividing the global result by the number of items. Scores higher than 30 indicate high levels of dissociation and are frequently reported in psychiatric patients with dissociative symptoms, while scores higher than 40 are related to post-traumatic stress disorder. Dissociation occupies an important position in the genesis of emotional manifestations in patients affected by cancer. In cancer, dissociative or post-traumatic symptoms can be related to coping strategies of anxious preoccupation and cognitive avoidance. |
6 months. Time 0: the day of the beginning of the treatment (surgery or radio-chemotherapy), and Time 1: 6 months from the first assessment. | |
Secondary | Evaluate quality of life dimensions in cervical cancer patients | The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Module (EORTC QLQ - CX24) is a Quality of Life questionnaire, designed to assess disease-specific and treatment-specific aspects of QoL in patients with cervical cancer.
The QLQ-CX24 consists of 3 multi-item scales and 5 single-item scales which analyzed 3 dimensions: Symptom Experience; Body Image; Sexual/Vaginal Functioning. All subscales have a minimum score of 0 (no symptoms) and a maximum score of 4 (high presence of symptoms). In general, high scores indicate dysfunctional or pathological characteristics. |
6 months. Time 0: the day of the beginning of the treatment (surgery or radio-chemotherapy), and Time 1: 6 months from the first assessment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03225443 -
Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT01373723 -
Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer
|
N/A | |
Completed |
NCT02808832 -
An HPV Vaccine Provider Intervention in Safety Net Clinics
|
N/A | |
Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
Terminated |
NCT01194609 -
A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01014026 -
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
|
Phase 3 | |
Terminated |
NCT01075412 -
FLT PET Imaging for Cervical Cancer
|
Phase 2 | |
Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
Completed |
NCT00377845 -
Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
|
Phase 0 | |
Recruiting |
NCT05531981 -
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
|
||
Recruiting |
NCT05393440 -
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
|
Phase 1 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT02866006 -
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
Completed |
NCT02320578 -
2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Not yet recruiting |
NCT05065853 -
Urinary and Vaginal HPV Testing in Cervical Cancer Screening
|
||
Completed |
NCT01231945 -
Low-Cost Molecular Cervical Cancer Screening Study
|
N/A | |
Completed |
NCT01717391 -
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
|
Phase 2 | |
Active, not recruiting |
NCT04947605 -
Epidemiological Landscape of Cervical Cancer in Latin America
|